Search Results for:
-
HEMOSOL COMPLETES OFFERING
The shares will be listed on the Toronto Stock Exchange under the symbol HDLBioWorld Today | Tuesday, April 20, 1993 -
PHARMACEUTICAL INDEX STARTS TRADING
The American Stock Exchange on Monday began trading the first long-term options or LEAPS (long-term equity anticipation securities) on its pharmaceutical index (ASE:DGR...The DRG LEAPS Index is valued at 1/10 the stock exchange's pharmaceutical indexBioWorld Today | Tuesday, April 13, 1993 -
CANGUARD CHANGES ITS NAME
The company retains the same trading symbol on the Vancouver Stock ExchangeBioWorld Today | Monday, April 12, 1993 -
THE CANADIAN ROUTE TO GOING PUBLIC
began trading on the Alberta Stock Exchange on Tuesday under the symbol VBL.A. VitaMed retains control of the Canadian public company and will continue operating in the U.S...The Alberta and Vancouver stock exchanges are among the only exchanges in the world that allow public venture financing, said Doug Ford, a merchant banker with Vancouver- based Enterprise Development CorpBioWorld Today | Wednesday, April 7, 1993 -
CANGUARD RAISES $477,000
Canguard's stock is traded on the Vancouver stock exchange under the symbol CGD. -- Jennifer Van Brunt (c) 1997 American Health ConsultantsBioWorld Today | Tuesday, April 6, 1993 -
HYGEIA IND FOR MAB TO TREAT CANCER
San Diego-based Hygeia, whose stock trades on the Vancouver stock exchange as HYG, has filed patent applications on both the antigen and the attendant antibodies, Brown told BioWorld. (c) 1997 American Health ConsultantsBioWorld Today | Monday, April 5, 1993 -
CELLTECH RAISES $5 MILLION
Celltech intends to seek a listing for its shares on the London Stock Exchange in fiscal 1993/94. (c) 1997 American Health ConsultantsBioWorld Today | Tuesday, March 16, 1993 -
OSTEX SUPPLIES BONE-LOSS TEST REAGENT
The university receives licensing fees, research grants and company stock in exchange for an exclusive license to commercialize the bone loss and related technologiesBioWorld Today | Wednesday, March 10, 1993 -
CHANGES AFOOT ON LONDON EXCHANGE
The biggest stumbling block in the London Stock Exchange's stringent listing criteria was the requirement that any company seeking to be listed had to show a five-year profit record...The stock exchange made a tremendous move, especially when you consider its historically deliberate and careful way of handling itself." -- Jennifer Van Brunt Senior Editor (c) 1997 American Health ConsultantsBioWorld Today | Monday, February 22, 1993 -
U.K. FIRMS FIND GREENER PASTURES IN U.S.
There are proposals afoot in Britain to relax the London Stock Exchange's rules for emerging pharmaceutical companies "without an adequate record" to obtain a full listing on the exchangeBioWorld Today | Monday, February 22, 1993 -
EPIGEN FILES BROAD PATENT ON CARCINOMA ANTIGEN
Epigen, whose shares are traded in the American Stock Exchange's Emerging Company Marketplace, closed Tuesday at $1.88, down 13 cents a shareBioWorld Today | Wednesday, February 10, 1993 -
GLYKO LURES CANADIAN AND EUROPEAN INVESTORS
Glyko completed its initial public offering through its new Canadian holding company, Glyko Biomedical Ltd. (GBL), on the Toronto Stock Exchange on Dec. 21, 1992, selling 2.9 million shares at $2.75 (Canadian) per share, raising $7.9 million (Canadian), that is, $6.3 million (U.SBioWorld Today | Wednesday, February 3, 1993 -
VIRATEK COMPLETES OFFERING OF UNITS
The units consist of one share of Viratek common stock and one common stock purchase warrant, and are traded on the American Stock Exchange (ASE:VRAE...The common stock of Viratek is also traded on the American Stock Exchange under the symbol VRA. (c) 1997 American Health ConsultantsBioWorld Today | Tuesday, February 2, 1993 -
GENELABS MERGES DIAGNOSTICS DIVISION
Genelabs said it expects to purchase the remaining outstanding shares of DBL common stock in a non-cash stock exchange valued at approximately $8.5 millionBioWorld Today | Wednesday, January 27, 1993 -
VIRATEK FILES FOR OFFERING
Calif., company (ASE:VRA), which began trading on the American Stock Exchange on Monday, will use the proceeds in part to fund Phase III clinical trials of its anti- viral compound Virazole (ribavirin) for treating hepatitis C. Viratek's stock closed down $1 a share on Wednesday to $8. (c) 1997 American Health ConsultantsBioWorld Today | Thursday, November 19, 1992 -
TRADING DATE FOR BIOTECH INVESTORS
The Chicago Board Options Exchange and the American Stock Exchange said Friday that trading will begin Oct. 9 in the CBOE Biotech Index and the AMEX Biotechnology Index, pending the approval of the Security and Exchange Commission...Kathy Fitzpatrick, manager of derivative securities communication for the American Stock Exchange, said the equal-dollar system is intended to "provide a more-rounded measure of the whole industryBioWorld Today | Monday, September 28, 1992 -
STOCK INDEXES READY TO BEGIN TRADING
The American Stock Exchange (ASE), which filed last January with the SEC to trade its own option index based on an underlying collection of biotechnology stocks, said Tuesday that it too is ready to launch an indexBioWorld Today | Wednesday, September 9, 1992 -
BRITISH BIO-TECH MAKES INDEX
British Bio-technology Group PLC will be included in the Financial Times' 500 share index as of this month, the London Stock Exchange announced FridayBioWorld Today | Wednesday, September 2, 1992 -
STOCK INDEXES POISED TO START TRADING
At least that's an optimistic view from an official of the American Stock Exchange, which had initially hoped to roll out its AMEX Biotechnology Stock Index onto the trading floor last AprilBioWorld Today | Monday, July 20, 1992 -
BRITISH SEEK ACCEPTANCE WITH TWO IPO LAUNCHES
BBTG claims to be the first biotechnology stock listed on the London Stock Exchange...The requirements of the London Stock Exchange are such that they don't encourage young companiesBioWorld Today | Thursday, July 2, 1992
Category
Current Filters
- xStock Exchange
Related Keywords
Categories
- x BioWorld Insight (1572)
- x BioWorld Today (985)
- x BioWorld International (514)
- x State of the Industry Report (196)
- x BioWorld Snapshots (13)
- x Bio Perspectives (11)
- x BioWorld Genomics Review (7)
- x Executive Compensation Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.